The fungal pathogen Pneumocystis spp. is a major cause of severe lung infection in immunocomprised patients. Using a novel technique to label surface proteins of live Pneumocystis murina, we have identified and squenced an abundant but previously uncharacterized surface peptidase, designated SPD 1. Serum from immunocompetent mice that cleared P. murina infection contained antibodies to SPD 1, and vaccination with the N terminal region of SPD 1 generated IgG antibodies to Pneumocystis. Importantly, vaccination of mice with SPD 1 followed by depletion of CD4+ T-cells was protective against experimental infection with P. murina. These results lead to our hypothesis that a protective immune response to Pneumocystis requires humoral immunity to SPD1. We will test this hypothesis in two Specific Aims.
In Specific Aim 1 we will seek to develop a more effective vaccine using SPD 1 protein fragments and will examine the role of memory B-cells in the immune response. Mucosal vaccination strategies will also be used to enhance the host response in lung tissue.
In Specific Aim 2 we will develop and characterize monoclonal antibodies to SPD 1 and will use these antibodies in passive vaccination strategies to treat established infection with P. murina. The results of these studies will lead to new information about the humoral immune response in host defense against Pneumocystis and will lead to new therapies to prevent or treat pulmonary infection with this important human pathogen.

Public Health Relevance

This project will investigate a novel vaccine for pneumonia caused by the fungal pathogen Pneumocystis. Preliminary data show that mice immunized with SPD1 are protected against this infection. This research will lead to exciting data to explain why this vaccine has a protective function and to novel approaches to vaccinate individuals with weakened immune systems such as in HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI121731-02
Application #
9238661
Study Section
Vaccines Against Microbial Diseases Study Section (VMD)
Program Officer
Zou, Lanling
Project Start
2016-03-08
Project End
2018-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
2
Fiscal Year
2017
Total Cost
$213,788
Indirect Cost
$57,012
Name
Louisiana State Univ Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Ruan, Sanbao; Cai, Yang; Ramsay, Alistair J et al. (2017) B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection. Vaccine 35:672-679
Samuelson, Derrick R; de la Rua, Nicholas M; Charles, Tysheena P et al. (2016) Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia. J Immunol 196:2655-65